BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cytochroma Inc. to Present at Upcoming Investor Conferences


9/7/2011 11:19:13 AM

MARKHAM, ON, Sept. 7, 2011 /PRNewswire/ -Cytochroma today announced that the Company will be presenting a corporate overview at the following investor conferences:

  • Charles W. Bishop, Cytochroma's President and Chief Executive Officer will be presenting at the Stifel Nicolaus Healthcare Conference 2011 at 4:25 PM ET on Wednesday, September 7, 2011 at the Four Seasons Hotel in Boston.
  • Eric J. Messner, Cytochroma's Chief Operating Officer will be presenting at the RW Baird 2011 Health Care Conference at 1:45 PM ET on Thursday, September 8, 2011 at The New York Palace Hotel in New York City.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio of CYP24 and phosphate-uptake inhibitors in early stage development.

For more information about Cytochroma, please visit www.cytochroma.com.

SOURCE Cytochroma



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES